echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Genting Xinyao Goshatuomab was awarded Orphan Drug Designation by MFDS in South Korea

    Genting Xinyao Goshatuomab was awarded Orphan Drug Designation by MFDS in South Korea

    • Last Update: 2021-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Genting Shinyao announced today that Gosartuzumab has obtained orphan drug designation granted by South Korea’s MFDS, which is used to treat locally unresectable advanced or metastatic triple-negative breasts that have received at least two lines or more of previous treatment.


    Triple negative breast cancer (TNBC) is a highly aggressive disease that accounts for approximately 15% of all breast cancer types worldwide.


    In recent decades, the incidence of breast cancer in South Korea has been among the highest in the world.


    Sacituzumab govitecan-hziy (Gosartuzumab) is a first-of-its-kind antibody-drug conjugate with a target of TROP-2, which is a membrane antigen that is overexpressed in many common epithelial cancers.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.